MedTrace Logo

Fedratinib in Combination With Nivolumab

NCT05393674 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-08

No results posted yet for this study

Summary

A multicenter, open-label, single arm, phase II study investigating the clinical efficacy of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment

Conditions

  • Primary Myelofibrosis
  • Secondary Myelofibrosis

Interventions

DRUG

Fedratinib Oral Capsule [Inrebic]

400 mg once daily p.o. from cycle 1-n, dose adjustment will be made according to the protocol

DRUG

Nivolumab

240 mg every 2 weeks i.v. from cycle 2-n

Sponsors & Collaborators

  • Prof. F. Heidel, MH Hannover

    collaborator UNKNOWN

  • Celgene International II S.á.r.l.

    collaborator UNKNOWN

  • Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

    lead OTHER

Principal Investigators

  • Salah-Eddin Al-Batran, Prof. Dr. · Institut für Klinische Krebsforschung IKF GmbH

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-14
Primary Completion
2025-11-05
Completion
2026-01-15

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05393674 on ClinicalTrials.gov